Endocannabinoids And Traumatic Brain Injury

Traumatic Brain Injury

Key Findings

In response to traumatic brain injury, there is local and transient accumulation of 2-AG at the site of injury, peaking at 4 h and sustained up to at least 24 h. Neuroprotection exerted by exogenous 2-AG suggests that the formation of 2-AG may serve as a molecular regulator of pathophysiological events, attenuating the brain damage. Data suggests that the functional interaction between 2-AG and ET-1 may provide a potential alternative pathway for abrogating ET-1-inducible vasoconstriction after brain injury and play a role in the neuroprotective effects exerted by 2-AG, as a potent vasodilator.

Information and Links


Link: Endocannabinoids And Traumatic Brain Injury

Year: 2007

DOI: 10.1007/s12035-007-8008-6


Ratings

(How Ratings Work)

Traumatic Brain Injury — 2


Possible to probable range of efficacy of cannabis for treatment of Traumatic Brain Injury according to the results found in this study.

Drugs Used

2-AG

SR-141716A